



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 05-06-2009

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 22-05-2009 TO BE PUBLISHED 08-06-2009 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000

<u>18-05-2009</u>		
417/2009	Schering corporation, USA (Priority 19-05-2008 USA)	“Heterocyclic compounds as factor IXA inhibitors”
418/2009	Muhammad Rauf, Nida Saleem, Khalid Jamil, Askari Begum, PCSIR, Karachi, Pakistan	“A process for the production of date squash from yellow dates (Khalal Stage)”
419/2009	Sanofi-Aventis Deutschland GmbH., Germany (Priority 20-05-2008 Europe)	“Drive assembly suitable for use in drug delivery device and drug delivery device”
420/2009	Otsuka America Pharmaceutical, Inc., USA (Priority 19-05-2008 USA)	“Method and apparatus for preparing a solution of a shear sensitive material”
421/2009	The Protector & Gamble Company, USA (Priority 19-05-2008 USA)	“Treatment of Heart Failure in Women”
<u>19-05-2009</u>		
422/2009	Siemens VAI Metals Technologies GmbH & Co., Austria (Priority 06-06-2008 Austria)	Method for controlling a transformation process"
423/2009	SmithKline Beecham Corporation, USA (Priority 19-02-2007 USA)	“Salt of purine derivatives as immunomodulators”
<u>20-05-2009</u>		
424/2009	Dr. Nighat Afza, Dr. Sadia Ferheen, Mr. Mahboob Ali Kalhoro,	“A process for the production of health care malt syrup “Maltirovit”

	<p>Mr. Agha Nisar Ahmed, Dr. Shazia Yasmeen, Mr. Muhammad Aijaz Anwar, Mr. Rashid Ali Khan, Mrs. Samra Usman, PCSIR, Karachi, Pakistan</p>	
425/2009	<p>Dr. Nighat Afza, Mrs. Farzana Azmat, Dr. Shazia Yasmeen, Mr. Mahboob Ali Kalhoro, Mr. Muhammad Aijaz Anwar, Mr. Rashid Ali Khan, Mr. Muhammad Farhan, Dr. Sadia Ferheen, Mrs. Samra Usman, PCSIR, Karachi, Pakistan</p>	<p>“A process for the production of buffalo colostrum powder-A dietary supplement”</p>
426/2009	<p>AstraZeneca AB, Sweden Bayer Scheringn Pharma AG, Germany (Priority 20-05-2008 USA)</p>	<p>“Phenyl and benzodioxinyl substituted indazoles derivatives”</p>
427/2009	<p>AstraZeneca AB, Sweden Bayer Scheringn Pharma AG, Germany (Priority 20-05-2008 USA)</p>	<p>“Phenyl or pyridinyl substituted indazoles derivatives”</p>
428/2009	<p>Janssen Pharmaceutica N.V., Belgium (Priority 23-05-2008 USA)</p>	<p>“Substituted pyrrolidine amides as modulators of the histamine H3 receptor”</p>
	<u>21-05-2009</u>	
429/2009	<p>Evogene Inc. USA (Priority 22-05-2008 USA)</p>	<p>“Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency”</p>
430/2009	<p>Glaxo Group Limited, United Kingdom (Priority 23-05-2008 Europe)</p>	<p>“Compounds”</p>

431/2009	Novartis AG, Switzerland (Priority 23-05-2008 Europe)	“Quinoxaline- and quinoline- carboxamide derivatives”
432/2009	SECRET.	SECRET.
433/2009	SECRET.	SECRET.
434/2009	SECRET.	SECRET.
	<u>22-05-2009</u>	
435/2009	Otsuka Pharmaceutical Co., Limited. Japan (Priority 23-05-2008 Japan)	“Powder inhalator”
436/2009	Amira Pharmaceuticals, INC USA (Priority 23.05.2008 USA)	“5-Lipoxygenase-Activating protein inhibitor”
437/2009	Wyeth, USA MedImmune Limited, United Kingdom. (Priority 23.05.2008 USA)	“Interleukin-21 receptor binding proteins”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

616/2000	F. Hoffmann-La Roche AG, Switzerland	“Erythropoietin conjugate with polyethylenglycol” A61K 47/48
----------	--	---


140091

A conjugate, said conjugate comprising an erythropoietin glycoprotein having at least one free amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or by the rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein via a linker of the formula -C(O)-X-S-Y- with the C(O) of the linker forming an amide bond with one of said amino groups,

X is $(\text{CH}_2)_K$ -or- $\text{CH}_2(\text{O}-\text{CH}_2-\text{CH}_2)_K$ -,

K is from 1 to 6

Y is



the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons.


824/2000 Bayer
Aktiengesellschaft,
Germany

“Novel aminodicarboxylic compound”

A61P 9/00

140092

The present invention relates to the compound of the formula (I)



Wherein R^1 , R^2 , R^3 , V, Q, Y, W, X, U, A and m are as defined, for the treatment of cardiovascular disorders, such as angina pectoris, ischaemia and cardiac insufficiency.

150/2005 Celanese International
Corporation,
USA

“Removal of permanganate reducing compound from methanol carbonylation process stream”

CO7C 51/48

140093

An improvement of the methanol carbonylation process for manufacturing acetic acid is disclosed.

Specifically disclosed is a method for removing permanganate reducing compounds ("PRC's") from the condensed light ends overhead stream, including (a) distilling at least a portion of the condensed light ends overhead to yield a PRC enriched second overhead stream; (b) extracting the second overhead stream with water and separating therefrom an aqueous stream containing PRC's; and (c) returning at least a portion of the extracted second overhead to the second distiller.

761/2007 F, Hoffmann-La Roche
AG.,
Switzerland

“A process for the preparation of erythropoietin conjugate with polyethylenglycol”

A61K 47/48

140094

A process for the preparation of erythropoietin conjugate with polyethylenglycol is disclosed, said conjugates comprise an erythropoietin glycoprotein having at least one free amino group and having the in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells and selected from the group consisting of human erythropoietin and analogs thereof which have the primary structure of human erythropoietin modified by the addition of from 1 to 6 glycosylation sites or by the rearrangement of at least one glycosylation site; said glycoprotein being covalently linked to from one to three lower-alkoxy poly(ethylene glycol) groups, each poly(ethylene glycol) group being covalently linked to the glycoprotein via a linker of the formula -C(O)-X-S-Y- with the C(O) of the linker forming an amide bond with one of said amino groups, wherein X and Y are as defined in the description and claims, the average molecular weight of each poly(ethylene glycol) moiety is from about 20 kilodaltons to about 40 kilodaltons, and the molecular weight of the conjugate is from about 51 kilodaltons to about 175 kilodaltons.


400/2009 Bayer
Aktiengesellschaft,
Germany

“Process for the preparation of novel aminodicarboxylic acid compound”

A61P 9/00

140095

The present invention relates to the process for the preparation of compound of the formula (I)



Wherein R^1 , R^2 , R^3 , V , Q , Y , W , U , A and m are as defined, for the treatment of cardiovascular disorders, such as angina pectoris, ischaemia and cardiac insufficiency.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139854	AstraZeneca UK Limited. United Kingdom.	241/2000
139855	SmithKline Beecham Corporation, USA.	795/2000
139856	Syngenta Participations AG. Switzerland	125/2002
139857	BASF. Aktiengesellschaft. Germany	826/2002
139858	Mitsubishi Tanabe Pharma Corporation. Japan	679/2004
139859	Syngenta Participations, AG. Switzerland	1022/2005

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488